Prolor Biotech (PBTH +4.9%) reports positive pre-clinical results from an animal study for its...
Prolor Biotech (PBTH +4.9%) reports positive pre-clinical results from an animal study for its obesity and Type II diabetes drug candidate MOD-6030. When administered once a week over 30 days, PBTH says the treatment produced an average weight loss of 28% and a 19% reduction in blood glucose levels.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs